1 of 1
Story summary
- A study presented at the American Society of Clinical Oncology (ASCO) shows GLP-1 drugs Ozempic and Wegovy may cut colon cancer risk by 36% vs aspirin.
- The analysis used health records from over 281,000 individuals.
- Among people with a family history of colon cancer, risk reduction reached 42%.
- GLP-1 drugs are used by about 6% of Americans, potentially benefiting 20 million people.
- Further trials are planned to validate these findings.
